In our hands, genetic or pharmacological targeting of NHERF1 was sufficient to prime an ‘autophagy-to-apoptosis switch’ that strikingly impacted the fate of CRC cells during β-catenin knockdown. The gene discussed is NHERF1; the disease is colorectal carcinoma.